$BIOA News

BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off

BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate

BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?

Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?

BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

BioAge Labs Doses First Participant Dosed In QUELL-CV

BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

Roth Capital Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $36

BioAge Labs to Present at Upcoming Investor Conferences

Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage?

Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33

BTIG Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $40